EC Number   |
|---|
   1.3.1.118 | expressed with N-terminal hexa-histidine motifs in Escherichia coli BL21 (DE3) pLysS cells |
| 1.3.1.118 | expression in Escherichia coli (BL21) |
| 1.3.1.118 | expression in Escherichia coli BL-21 |
| 1.3.1.118 | expression in Escherichia coli BL21 (DE3) |
| 1.3.1.118 | expression in Escherichia coli BL21(DE3)pLysS |
| 1.3.1.118 | expression of InHA-6xHis protein in Escherichia coli (BL21) |
| 1.3.1.118 | expression Saccharomyces cerevisiae etr1D cells lacking Etr1p, the 2-trans-enoyl-thioester reductase of mitochondrial type 2 fatty acid synthase. Yeast mitochondria are used as a surrogate compartment for hosting the drug-target protein InhA from mycobacterial FASII. The heterologous enzyme is ectopically expressed in a yeast mutant strain from which the native gene encoding the corresponding mitochondrial FASII enzyme is missing. Using an appropriate fungal mitochondrial leader sequence, the mycobacterial protein is directed to the mitochondria, where it can rescue the respiratory growth phenotype of the mutant. The rationale behind the assay is that added antimycolates are foreseen to inhibit the mycobacterial enzyme, thereby recreating the respiratory deficiency of the original mutant, discernible as poor colony formation and growth on glycerol medium |
| 1.3.1.118 | overexpressed in Escherichia coli |
| 1.3.1.118 | overexpression in Escherichia coli |
| 1.3.1.118 | the inhA gene is cloned into the pMK1 mycobacterial expression vector under the control of the strong promoter hsp60. The resulting construct is used to transform Mycobacterium bovis BCG Pasteur in order to allow overproduction of recombinant His-tagged InhA |
